The cardiac potassium channel hERG (human ether-a-go-go-related gene) encodes the α-subunit of the rapid delayed rectifier current I Kr in the heart, which contributes to terminal repolarization in human cardiomyocytes. Direct block of hERG/I Kr channels by a large number of therapeutic compounds produces acLQTS [acquired LQTS (long QT syndrome)] characterized by drug-induced QT prolongation and torsades de pointes arrhythmias. The cardiotoxicity associated with unintended hERG block has prompted pharmaceutical companies to screen developmental compounds for hERG blockade and made hERG a major target in drug safety programmes. More recently, a novel form of acLQTS has been discovered that may go undetected in most conventional safety assays. Several therapeutic compounds have been identified that reduce hERG/I Kr currents not by direct block but by inhibition of hERG/I Kr trafficking to the cell surface. Important examples are antineoplastic Hsp90 (heat-shock protein 90) inhibitors such as (i) geldanamycin, (ii) the leukaemia drug arsenic trioxide, (iii) the antiprotozoical pentamidine, (iv) probucol, a cholesterol-lowering drug, and (v) fluoxetine, a widely used antidepressant. Increased awareness of drug-induced hERG trafficking defects will help to further reduce the potentially lethal adverse cardiac events associated with acLQTS.
from the marketplace, including strong-selling compounds such as terfenadine (Seldane) and cisapride (Propulsid). The well-recognized susceptibility of hERG to block by small organic molecules has now been attributed to several unique structural features of the hERG channel [5] . First of all, the promiscuous high-affinity drug-binding site of hERG has been located to the central cavity/conduction pathway of the channel protein, which holds hydrated potassium ions on their approach to the selectivity filter once the cytoplasmic gate has opened. Consequently, most blockers bind only after they gain access to the central cavity, which appears to be larger than in most other potassium channels and is therefore able to trap blocking molecules after closure of the activation gate. Another crucial component of high-affinity drug binding originates from two concentric rings of aromatic amino acid side chains stacked on top of each other in the central cavity. Work by Sanguinetti and Mitcheson [5] suggests that the surprising diversity and high affinity of hERG blockers depend to a large extent on cation-π interactions between a positively charged tertiary amine present in most blocking molecules and the π -electrons of Tyr 652 , which is located in the S6 transmembrane domain and thought to project directly into the central cavity of hERG. Drug-channel interactions are further stabilized by strong, hydrophobic π -π interactions between rigid, planar aromatic elements present in therapeutic compounds and the π -electrons of Phe 656 , which is similarly located in S6. The tremendous progress made towards a mechanistic understanding of the 'universal' drug-binding site of hERG may be exploited in the near future to avoid unintended drug-channel interactions early during drug development using computational methods. However, acLQTS due to unintended block of hERG is even today largely preventable by removing drugs from the market place once they have been linked to adverse cardiac events and restricting the use of others. Moreover, novel guidelines for the development of therapeutic compounds are currently being instituted by regulatory agencies that should reduce the incidence of acLQTS by making measurement of direct hERG block mandatory using either ion flux, binding or electrophysiological assays including patch-clamp measurements, the current gold standard in hERG safety testing [6, 7] .
Drug-induced LQTS by inhibition of hERG channel trafficking
More recently, however, we have described a novel mechanism for acLQTS that may go undetected in most conventional safety studies which are geared towards identification of direct hERG blockers. We have shown that at least three therapeutic compounds reduce hERG/I Kr currents not by direct block but by inhibition of hERG/I Kr trafficking to the cell surface: (i) arsenic trioxide, which is used in the treatment of acute promyelocytic leukaemia [8] , (ii) the antiprotozoical agent pentamidine [9] , and (iii) cardiac glycosides, which are still in use for the treatment of heart failure [10] . Although the full extent of this gap in hERG safety testing is currently not clear, it is important to note that the list of therapeutic compounds that induce hERG trafficking inhibition is steadily growing. The latest additions include probucol, a cholesterol-lowering drug long associated with acLQTS [11] , and the antidepressant fluoxetine (Prozac), which represents the first well-documented member of a potentially large group of compounds that directly block hERG and inhibit its trafficking at the same time [12, 13] .
Hsp90 (heat-shock protein 90) inhibitors block hERG trafficking
In inherited LQTS2, a large group of mutations produces trafficking-deficient hERG channels that are retained in the ER (endoplasmic reticulum) by quality-control mechanisms which are able to detect minute deviations from the native, exportable channel conformation [14] . Importantly, many of these mutant channels can adopt a conformation that will reach the cell surface and produce functional channels on incubation with chemical and pharmacological chaperones or at low incubation temperature. Since 'channel rescue' may provide a therapeutic window, it is imperative to gain a better understanding of the molecular mechanisms guiding hERG processing and trafficking to the cell-surface membrane. However, our knowledge of hERG channel folding and assembly, ER export, trafficking through the Golgi apparatus as well as stability at and removal from the cell surface is limited. To the best of our knowledge, only few proteins have been identified in the entire hERG trafficking pathway including three chaperones, Hsp70, Hsp90 [15] , calnexin [16] , a Golgi-resident protein, GM130 (Golgi matrix protein of 130 kDa) [17] and 14-3-3 protein, a classical adaptor protein with putative chaperone functions [18] . Of all these proteins, Hsp90 is probably best characterized [15] . It is generally assumed that Hsp90 assists with late folding steps, i.e. catalyses conformational transitions close to the native conformation of a client protein. Consequently, inhibition of Hsp90 is thought to prevent maturation of client proteins and often promotes their degradation. Similarly, inhibition of Hsp90 function with geldanamycin prevents maturation of hERG wild-type channels in the ER and reduces hERG/I Kr currents at the cell surface. A novel inhibitor of Hsp90 function that has been identified more recently in high-throughput screens is celastrol, which also reduces hERG maturation and cellsurface expression via an interaction site on Hsp90 distinct from the ATP-binding pocket used by the classical inhibitors geldanamycin and radicicol [19, 20] . Since small-molecule inhibitors of Hsp90 function, such as the geldanamycin derivative 17-AAG (17-allylamino-17-desmethoxygeldanamycin), are currently developed as cancer therapeutics [21] , we hypothesized that such molecules may cause acLQTS and increase cardiac risk, not by hERG block but by inhibition of hERG trafficking. Unfortunately, cardiac complications associated with acLQTS are rare and cannot be easily detected in small clinical trials conducted with experimental drugs such as 17-AAG. Thus we decided to test our 'trafficking' hypothesis by carefully analysing the mechanism for acLQTS of all those therapeutic compounds that had previously been associated with QT prolongation, TdP arrhythmias and sudden cardiac arrest, yet where no direct hERG block had been reported.
As a first example of a compound that disrupted hERG trafficking as a mechanism of acLQTS, we identified arsenic trioxide (As 2 O 3 ) [8] . Arsenic trioxide is in use worldwide for the treatment of patients with relapsed or refractory APL (acute promyelocytic leukaemia; see, e.g., [22] ). Not unexpectedly for a poisonous compound, the therapeutic use of As 2 O 3 in the treatment of APL is burdened by broad toxicity including QT prolongation, TdP arrhythmias and sudden cardiac death (see, e.g., [23] ). In our analysis of As 2 O 3 -induced cardiotoxicity, we found that As 2 O 3 produced its effects on the repolarization of cardiac myocytes, not by direct block of cardiac ion channels (but see also a report by Drolet et al. [24] proposing direct block of hERG by As 2 O 3 as a mechanism for acLQTS), but indirectly, by reducing surface expression of hERG/I Kr channels at clinically relevant concentrations of 0.1-3 µM. As 2 O 3 interferes with hERG trafficking probably by inhibiting the formation of channelHsp90 complexes. This interpretation is consistent with the hERG trafficking block observed with known Hsp90 inhibitors such as geldanamycin, radicicol and celastrol, although the precise mechanism of interaction with Hsp90 has not been determined for As 2 O 3 . hERG trafficking is also inhibited by cardiotoxic trivalent antimony compounds such as PAT (potassium antimony(III) tartrate], which is chemically similar to trivalent arsenic (both metalloids belong to group 15 of the periodic table) and has been used in the past in the treatment of leishmaniasis and schistosomiasis [25] . 
Additional small molecules that disrupt hERG trafficking
As a metalloid, arsenic represents an unusual therapeutic compound with broad activity against a multitude of cellular targets due to its high affinity for thiol groups and its propensity to induce oxidative stress in many different cell types. In contrast, pentamidine, another example of an hERG trafficking inhibitor, represents a more typical small organic molecule that is used in the U.S. as second line treatment of Pneumocystis carinii pneumonia, a common opportunistic infection in patients with impaired immune function (see, e.g., [26] ). Therapy with pentamidine was long known to be accompanied by prolongation of the QT interval and, in some instances, by TdP arrhythmias and sudden cardiac death, although direct hERG block could not be demonstrated in a clinically relevant concentration range [27] . In contrast, clinically relevant concentrations of pentamidine disrupted hERG trafficking ( Figure 1 ) and reduced hERG currents in heterologous expression systems as well as in cardiac myocytes, with cardiac repolarization being delayed as a direct consequence [9, 27] . Furthermore, it has been shown more recently that probucol, a cholesterol-lowering therapeutic compound associated with acLQT, selectively reduces hERG/I Kr currents and prolongs the cardiac action potential via inhibition of hERG trafficking [11] . Finally, fluoxetine has been described in more detail as an hERG trafficking inhibitor [12] . Fluoxetine is a widely prescribed antidepressant inhibiting serotonin re-uptake in the brain, which was known to directly block hERG at concentrations reached in the clinic on overdosing. While it has been thought previously that direct hERG block may provide an explanation for the rare cases of acLQTS observed with fluoxetine, it is now becoming clear from work by January and coworkers that fluoxetine produces acLQTS probably via a dual mechanism that includes both direct channel block as well as inhibition of hERG channel trafficking [12] . All of these examples emphasize the role played by hERG trafficking inhibition as a novel mechanism for acLQTS syndrome.
However, it is important to point out that in marked contrast with direct hERG block, only little is known about the precise mechanisms of drug-induced trafficking inhibition of hERG channels for small organic molecules such as pentamidine, probucol or fluoxetine. In addition, it is not clear how prevalent the phenomenon of drug-induced hERG trafficking block is for therapeutic compounds that are currently in use or under development and whether certain compound classes exist that are particularly prone to inhibit hERG trafficking.
Thus the systematic identification of novel compound classes that reduce cell-surface expression of hERG with high specificity is important. To accomplish this goal, a highthroughput antibody-based chemiluminescent assay (hERGLite) has been developed to monitor changes in heterologous expression of hERG channels at the cell surface as a function of drug exposure [13] . Using this assay, several additional putative hERG trafficking inhibitors have been identified (ivermectin, ethacrynic acid and bufexamac) as well as a potentially large group of compounds that both block hERG and inhibit hERG trafficking, as has been described for fluoxetine [12, 13] . One of the most surprising discoveries using hERG-Lite was the identification of cardiac glycosides as a novel compound class that decreases hERG surface trafficking with nanomolar affinity [10] . Cardiac glycosides are wellknown specific inhibitors of Na + /K + -ATPases, the molecular pumps that maintain the steep Na + and K + ion gradients at the plasma membrane, and have never before been associated with acLQTS despite long-standing use in the treatment of congestive heart failure and/or atrial fibrillation (see, e.g., [28] ). Out of 11 different cardiac glycosides that disrupt hERG trafficking, digoxin, digitoxin and ouabain have been analysed in detail. All three compounds inhibit hERG surface expression in the nanomolar concentration range by blocking hERG channel exit from the ER (Figure 2 ). These effects were specific, since neither hKv1.5, KvLQT1/mink nor several cardiac membrane currents were affected, and could be extended to native hERG/I Kr currents expressed in ventricular myocytes. These results raise the possibility that hERG trafficking inhibition may contribute to the complex ECG (electrocardiogram) changes seen with cardiac glycosides in the clinic. Most interestingly, they also suggested that the cardiac-glycoside-mediated trafficking inhibition was linked to direct inhibition of the Na + /K + pump and was not caused by off-target effects, e.g. the inhibition of proteins in the hERG processing pathway. To probe the molecular mechanism that couples Na + /K + pumps at the level of the cell-surface membrane with hERG processing and folding in the ER, several signalling pathways as well as changes in intracellular ion composition will have to be analysed in future experiments.
Conclusions and future directions
Although the most common mechanism underlying acLQTS is the direct blockade of hERG/I Kr potassium channels by therapeutic compounds, disruption of hERG trafficking has now emerged as an additional, novel mechanism for acquired QT prolongation by some agents, including inhibitors of Hsp90 function such as geldanamycin, radiciol, 17-AGG, the metalloids arsenic trioxide and potassium antimony tartrate, as well as small organic molecules such as pentamidine, probucol and fluoxetine. Among these compounds fluoxetine stands out, since it may represent the first example of a large group of compounds that block hERG and disrupt its trafficking at the same time. Undoubtedly, the discovery of drug-induced trafficking defects of hERG and possibly also other ion channels [20] poses a challenge for commonly applied safety assays which are geared towards acute channel blockade. To determine and minimize the risk associated with putative drug-induced trafficking defects for the drug discovery process, it may be necessary to screen for such compounds using high-throughput methods. Furthermore, a better mechanistic understanding of drug-induced trafficking defects may help to identify therapeutic compound classes that are particularly prone to the disruption of hERG channel processing and trafficking.
